Trials / No Longer Available
No Longer AvailableNCT02051673
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Talaris Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)
Detailed description
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) and living donor kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion | Enriched Hematopoetic Stem Cell Infusion |
Timeline
- First posted
- 2014-01-31
- Last updated
- 2022-07-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02051673. Inclusion in this directory is not an endorsement.